Surrozen, Inc./DE Stock-Based Compensation
Surrozen, Inc./DE (SRZN) reported Stock-Based Compensation of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.89M, a 191.05% increase year-over-year.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.10M, a 152.40% increase year-over-year.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.00M, a 11.33% increase year-over-year.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.00M, a 3.27% decline year-over-year.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for fiscal 2025 was $3.83M, a 6.78% decline from fiscal 2024.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for fiscal 2024 was $4.11M, a 5.90% decline from fiscal 2023.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for fiscal 2023 was $4.37M, a 3.21% decline from fiscal 2022.
- Surrozen, Inc./DE share-based payment arrangement, noncash expense for fiscal 2022 was $4.52M, a 95.03% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.00M 10-Q · filed 2026-08-06 | $6.00M derived: sum of 3 quarters · filed 2026-08-06 | $7.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-06 | $3.11M derived: sum of 2 quarters · filed 2026-05-06 | $4.11M derived: sum of 3 quarters · filed 2026-05-06 | $5.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.01M derived: sum of 2 quarters · filed 2026-03-23 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | $3.83M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.00M derived: sum of 2 quarters · filed 2026-08-06 | $2.83M 10-Q · filed 2025-11-07 | $3.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $994.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.83M 10-Q · filed 2026-08-06 | $2.73M derived: sum of 3 quarters · filed 2026-08-06 | $3.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $834.00K 10-Q · filed 2026-05-06 | $1.73M derived: sum of 2 quarters · filed 2026-05-06 | $2.77M derived: sum of 3 quarters · filed 2026-05-06 | $3.92M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.94M derived: sum of 2 quarters · filed 2026-03-23 | $3.08M derived: sum of 3 quarters · filed 2026-03-23 | $4.11M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.18M derived: sum of 2 quarters · filed 2025-11-07 | $3.21M 10-Q · filed 2025-11-07 | $4.39M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $2.17M 10-Q · filed 2025-08-08 | $3.35M derived: sum of 3 quarters · filed 2025-08-08 | $4.26M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-09 | $2.20M derived: sum of 2 quarters · filed 2025-05-09 | $3.12M derived: sum of 3 quarters · filed 2025-05-09 | $4.27M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.08M derived: sum of 2 quarters · filed 2025-03-31 | $3.24M derived: sum of 3 quarters · filed 2025-03-31 | $4.37M 10-K · filed 2025-03-31 |
| 2023-09-30 | $913.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.07M derived: sum of 2 quarters · filed 2024-11-06 | $3.20M 10-Q · filed 2024-11-06 | $4.75M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.29M 10-Q · filed 2024-08-12 | $3.83M derived: sum of 3 quarters · filed 2024-08-12 | $4.91M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.13M 10-Q · filed 2024-05-08 | $2.67M derived: sum of 2 quarters · filed 2024-05-08 | $3.75M derived: sum of 3 quarters · filed 2024-05-08 | $4.73M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $2.62M derived: sum of 2 quarters · filed 2024-04-10 | $3.60M derived: sum of 3 quarters · filed 2024-04-10 | $4.52M 10-K · filed 2024-04-10 |
| 2022-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.06M derived: sum of 2 quarters · filed 2023-11-08 | $2.97M 10-Q · filed 2023-11-08 | $3.67M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $979.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.90M 10-Q · filed 2023-08-09 | $2.59M derived: sum of 3 quarters · filed 2023-08-09 | $3.20M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $916.00K 10-Q · filed 2023-05-10 | $1.61M derived: sum of 2 quarters · filed 2023-05-10 | $2.23M derived: sum of 3 quarters · filed 2023-05-10 | $2.76M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.31M derived: sum of 2 quarters · filed 2023-03-31 | $1.84M derived: sum of 3 quarters · filed 2023-03-31 | $2.32M 10-K · filed 2023-03-31 |
| 2021-09-30 | $616.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.15M derived: sum of 2 quarters · filed 2022-11-14 | $1.62M 10-Q · filed 2022-11-14 | $1.81M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.01M 10-Q · filed 2022-08-11 | $1.19M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $475.00K 10-Q · filed 2022-05-11 | $662.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $635.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $448.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |